Andina III and EMMAC Life Sciences Limited said today they have mutually terminated negotiations regarding a proposed business combination. The parties signed a non-binding letter of intent on July 22, in which EMMAC was expected to trade on the NASDAQ. Both sides cited “challenging global economic conditions” among the reasons for terminating the deal. EMMAC bills itself as Europe’s largest independent cannabis company. Andina shareholders last week approved an extension of the SPAC’s deadline to close a deal. Andina was initially capitalized with a $100M IPO. Read more.
Related Posts
EF Hutton Acquisition Abandons $125M IPO
The SPAC, which registered the offering last November, had planned to focus on companies within the consumer and retail industry.
NextGen Lists Assets of $377M
The SPAC in its lastest filing cited unaudited assets of approximately $377 million as of Oct. 9.
Phoenix Biotech Adds PIPE, Adjusts CERo Deal Terms
CERo is an immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms.
Skydeck Acquisition Won’t Complete a Deal, Will Dissolve May 21
Skydeck was focused on media, technology, communications and digital health companies in the United States and other regions. Chairman Paul Salem for 27 years was a senior managing director on Providence Equity’s investment team.